Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1866 1
1968 1
1978 1
1983 1
1985 2
1986 2
1987 5
1988 3
1989 2
1990 1
1991 4
1992 5
1993 4
1994 5
1995 2
1996 9
1997 16
1998 8
1999 12
2000 17
2001 10
2002 8
2003 12
2004 8
2005 8
2006 8
2007 10
2008 6
2009 7
2010 4
2011 8
2012 15
2013 6
2014 4
2015 2
2016 7
2017 2
2018 3
2019 1
2020 1
2021 2
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 12215552

220 results

Results by year

Filters applied: . Clear all
Page 1
The PLACORHEN study: a double-blind, placebo-controlled, randomized radionuclide study with (186)Re-etidronate in hormone-resistant prostate cancer patients with painful bone metastases. Placebo Controlled Rhenium Study.
Han SH, de Klerk JM, Tan S, van het Schip AD, Derksen BH, van Dijk A, Kruitwagen CL, Blijham GH, van Rijk PP, Zonnenberg BA. Han SH, et al. J Nucl Med. 2002 Sep;43(9):1150-6. J Nucl Med. 2002. PMID: 12215552 Free article. Clinical Trial.
Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: tandomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate.
Palmedo H, Manka-Waluch A, Albers P, Schmidt-Wolf IG, Reinhardt M, Ezziddin S, Joe A, Roedel R, Fimmers R, Knapp FF Jr, Guhlke S, Biersack HJ. Palmedo H, et al. J Clin Oncol. 2003 Aug 1;21(15):2869-75. doi: 10.1200/JCO.2003.12.060. J Clin Oncol. 2003. PMID: 12885803 Clinical Trial.
Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.
James ND, Caty A, Borre M, Zonnenberg BA, Beuzeboc P, Morris T, Phung D, Dawson NA. James ND, et al. Eur Urol. 2009 May;55(5):1112-23. doi: 10.1016/j.eururo.2008.11.002. Epub 2008 Nov 29. Eur Urol. 2009. PMID: 19042080 Clinical Trial.
220 results